Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eye Drop Manufacturers Get Advice On Seeing Quality Clearly In US FDA Draft Guidance

Executive Summary

Need for guidance shown not only in recalls over past year of OTC eye drops due to bacterial contaminants found in products and insufficient sterility practices in facilities but also in warning letters sent in 2022 and 2023 to firms manufacturing Rx and OTC ophthalmic drugs.

You may also be interested in...

All About Eye Drops: Warnings To Six Homeopathic And Two Allopathic Firms; Seven US, One Swiss

Common across warnings is all the firms, retailers as well as manufacturers, are marketing OTC eye drops with noncompliant claims, including “prevent or improve cataracts” and “temporarily alleviate blepharitis symptoms.” One also had GMP problems.

US FDA Inspectors See Cloudy GMP Compliance At OTC Ophthalmic Drug Manufacturers

Agency warns two drug firms providing OTC eye drops about failing to maintain sanitary conditions after early in 2023 announcing Indian firm Global Pharma Healthcare made artificial tear products recalled due to potential infection from bacterial contamination not previously seen in US.

US FDA Wants Six-Month Premarket Notice Before Manufacturers’ First Monograph OTC Launches

Agency wants time to ensure compliance with GMP regulations before drug makers, such as an Indian firm which provided artificial tear eye drops currently on recall in the US after the products were linked to serious adverse events, distribute OTC monograph drugs for the first time.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts